Since January 2020 Elsevier has created a COVID-19 resource centre with free information in English and Mandarin on the novel coronavirus COVID-19. The COVID-19 resource centre is hosted on Elsevier Connect, the company's public news and information website.

Elsevier hereby grants permission to make all its COVID-19-related research that is available on the COVID-19 resource centre - including this research content - immediately available in PubMed Central and other publicly funded repositories, such as the WHO COVID database with rights for unrestricted research re-use and analyses in any form or by any means with acknowledgement of the original source. These permissions are granted for free by Elsevier for as long as the COVID-19 resource centre remains active.
Toxic shock-like syndrome and COVID-19: Multisystem inflammatory syndrome in children (MIS-C)

Andrea G. Greene, MD, MPH *, Mona Saleh, MD, Eric Roseman, MD, Richard Sinert, DO
SUNY Downstate Health Sciences University, 450 Clarkson Ave., Brooklyn, NY 11203, USA

ARTICLE INFO

Article history:
Received 26 May 2020
Accepted 31 May 2020

Keywords:
COVID-19
Pediatric
Coronavirus
Shock
Septic
Tocilizumab
Remdesivir
Child
Enoxaparin

ABSTRACT

Early reports of COVID-19 in pediatric populations emphasized a mild course of disease with severe cases disproportionately affecting infant and comorbid pediatric patients. After the peak of the epidemic in New York City, in late April to early May, cases of severe illness associated with COVID-19 were reported among mostly previously healthy children ages 5-19. Many of these cases feature a toxic shock-like syndrome or Kawasaki-like syndrome in the setting of SARS-CoV-2 positive diagnostic testing and the CDC has termed this presentation Multisystem Inflammatory Syndrome (MIS-C). It is essential to disseminate information among the medical community regarding severe and atypical presentations of COVID-19 as prior knowledge can help communities with increasing caseloads prepare to quickly identify and treat these patients as they present in the emergency department. We describe a case of MIS-C in a child who presented to our Emergency Department (ED) twice and on the second visit was found to have signs of distributive shock, multi-organ injury and systemic inflammation associated with COVID-19. The case describes two ED visits by an 11-year-old SARS-CoV-2 positive female who initially presented with fever, rash and pharyngitis and returned within 48 hours with evidence of cardiac and renal dysfunction and fluid-refractory hypotension requiring vasopressors and PICU admission.

1. Introduction

The coronavirus disease 2019 (COVID-19) pandemic has caused a total of nearly 300,000 deaths worldwide [1]. Pediatric patients PCR positive for SARS-CoV-2 present differently than adults with 40% either asymptomatic or with URI symptoms and commonly have pharyngeal erythema [2]. A recent systematic review article on COVID-19 reports a low pediatric prevalence [3]. On May 14, the CDC released a Health Advisory on a severe life-threatening complication of pediatric COVID-19 termed Multisystem Inflammatory Syndrome in Children (MIS-C) [4]. We describe a case of MIS-C in a child who presented to our Emergency Department (ED) twice and on the second visit was found to have signs of distributive shock, multi-organ injury and systemic inflammation associated with COVID-19.

2. Case description

Our patient is an 11-year-old fully immunized female with no past medical history who presented with 4 days of sore throat, malaise, poor appetite, generalized abdominal pain, leg pain, fever and an itchy rash starting on her palms that quickly spread to the trunk and back.

On initial presentation to our ED the patient was alert, non-toxic and in no acute distress. Vitals: febrile (39.3 °C) and tachycardic (126). Respiration and blood pressure were within normal limits. Physical exam: mild pharyngeal erythema, no exudates or palatal petechiae, no lymphadenopathy, mild dehydration, and a diffuse reticular, non-blanching papular rash on the bilateral upper extremities and abdomen (sandpaper) with palmar erythema. After a normal chest X-ray the patient’s fever resolved, she felt better, and was discharged with precautions to return if fever persisted or for worsening symptoms.

A follow-up phone call was made the day after discharge with patient and mother reporting minimal improvement and she returned to our ED. Two hours after ED arrival, Vitals: hypotensive (80/38 mmHg), tachypneic (34 b/min), febrile (39.1 °C) and tachycardic (113). Fluid boluses of 2 L failed to normalize BP or HR. EKG: sinus tachycardia and ST1Q3T3 without acute ischemia. Troponin and BNP were elevated to 0.112 (≤ 0.010 ng/mL) and 8718 (≤ 125 pg/mL), respectively. An elevated white blood cell count of 14.18 (4.00-12.5) and lymphopenia, normal platelets and increased PT/INR of 21.4 (9.4-12.5 s) and 1.9 (0.8-1.2 ratio), c-reactive protein >300 (0.10-2.80 mg/L), D-dimer 1207 (0-243 ng/mL D-DU), ferritin 1789 (13.00-150.00 ng/mL), lactate dehydrogenase 301 (120-300 U/L), procalcitonin 16.28 (0.00-0.50 ng/mL), and fibrinogen 597...
Vital signs at presentation included temperature of 39.0°C, heart rate 120 bpm, respiratory rate 32 bpm, and blood pressure 83/32 mmHg. Initial laboratory workup revealed metabolic acidosis with a pH 7.26, bicarbonate 10 mEq/L, and lactate 4.7 mmol/L. The patient had a white blood cell count of 24,600 cells/µL with 92% neutrophils, hemoglobin 10.8 g/dL, and platelets 84,000/µL. D-dimer was elevated to 11,515 (0.09 mg/mL), and troponin I was 0.15 ng/mL, up from 0.01 ng/mL on admission. C-reactive protein was elevated to 1449 (0.0 mg/dL) and creatinine 2.06 (0.53–0.79 mg/dL). The patient tested PCR positive for SARS-CoV-2. The differential diagnosis was toxic shock syndrome, cytokine storm, hemophagocytic lymphohistiocytosis, septic shock, atypical Kawasaki disease, or cardiogenic shock secondary to myocarditis vs. pulmonary embolism.

The patient was transferred to PICU already on milrinone and nor-epinephrine, an official echocardiogram: “LV systolic function mildly decreased based on decreased shortening fraction.” Furosemide was given. Empiric antibiotic coverage included ceftriaxone, clindamycin and piperacillin-tazobactam. Full-dose anticoagulation with enoxaparin was initiated and the patient was also given Vitamin K to correct elevated PT and INR. IL-6 was elevated to 1449 (0.0 mg/dL) and piperacillin-tazobactam. Full-dose anticoagulation with enoxaparin was started along with convalescent plasma and remdesivir. The patient received steroids and IVIG for possible incomplete Kawasaki. She improved dramatically; within ~24 h, she no longer required pressors and was afebrile without tachycardia.

Prior to discharge, EKG and echo were repeated. S1Q3T3 from the initial EKG had resolved. Repeat echo was performed on 5/5/20: “Normal biventricular function. No aneurysms noted in the proximal coronary artery network.” D-dimer was downtrending, troponemia had resolved and BNP was at baseline on discharge. The patient was sent home with instructions to continue with enoxaparin injections for two weeks followed by an appointment with pediatric hematology and pediatric cardiology.

3. Discussion

This is the first case report in our ED of MIS-C. A case report from India reported a similar presentation of an eight-year-old with sore throat, fever, abdominal pain and rash who was found to have fluid-refractory hypotension requiring pressors [5]. At the time of writing, multiple case reports on COVID-19 and atypical or incomplete Kawasaki disease have been published [6,7]. At least one case report has described a mixed picture of possible Kawasaki with features of MIS-C [5]. Our case described features more consistent with a toxic shock syndrome, but incomplete Kawasaki disease could not be excluded by the patient’s overall clinical picture. It is important to keep Kawasaki disease in mind for potential MIS-C patients because prompt treatment is low risk and may be beneficial [8]. Finally, earlier reports from China and the United States described infants as the most vulnerable pediatric population for severe COVID-19 [9,10]. This case occurred in an 11-year-old and it appears that thus far, MIS-C is more likely to affect children beyond infancy [4].

4. Conclusion

Emergency Department physicians should consider close follow-up for any pediatric patient presenting with fever >3 days during the COVID-19 pandemic who is stable for discharge and lacks other associated signs and symptoms of MIS-C.

Acknowledgements

Special thanks to the Kings County Hospital Center Emergency Department staff for their dedication and strength during the COVID-19 pandemic.

References

[1] Dong E, Du H, Gardner L. An interactive web-based dashboard to track COVID-19 in real time. Lancet Infect Dis. 2020;20(5):533-4. https://doi.org/10.1016/S1473-3099(20)30120-1.
[2] Lu X, Zhang L, Du H, et al. SARS-CoV-2 infection in children. N Engl J Med. 2020;382(17):1663-5. https://doi.org/10.1056/NEJMc2005073.
[3] Ludvigsson JF. Systematic review of COVID-19 in children shows milder cases and a better prognosis than adults. Acta Paediatr. 2020;109(6):1088-95. https://doi.org/10.1111/apa.15270.
[4] Centers for Disease Control and Prevention. Multisystem inflammatory syndrome in children (MIS-C) associated with coronavirus disease 2019 (COVID-19). https://emergency.cdc.gov/han/han0432.asp. [Accessed 26 May 2020].
[5] Balasubramanian S, Nagendran TM, Ramachandran B, Ramanan AV. Hyper-inflammatory syndrome in a child with COVID-19 treated successfully with intravenous immunoglobulin and tocilizumab. published online ahead of print, 2020 May 10 Indian Pediatr. 2020 [S097475591600180].
[6] Akgün A, Alim A, Akar S, et al. Kawasaki disease during the 2019 novel coronavirus disease (COVID-19) pandemic. published online ahead of print, 2020 May 13. Pediatr. 2020. https://doi.org/10.1542/peds.2020-0123hpeds.2020-0123.
[7] Verdoni L, Mazza A, Gervasoni A, et al. An outbreak of severe Kawasaki-like disease at the Italian epicentre of the SARS-CoV-2 epidemic: an observational cohort study [published online ahead of print, 2020 May 13]. Lancet. 2020. https://doi.org/10.1016/S0140-6736(20)31103-X. doi:.https://doi.org/10.1016/S0140-6736(20)31103-X.
[8] Harahsheh AS, Dahdah N, Newburger JW, et al. MIS-C diagnosis: novel virus and novel case. published online ahead of print, 2020 Apr 7 Hosp Pediatr. 2020. https://doi.org/10.1542/hpps.2020-0123 hpps.2020-0123.
[9] Harahsheh AS, Dahdah N, Newburger JW, et al. Missed or delayed diagnosis of Kawasaki disease during the 2019 novel coronavirus disease (COVID-19) pandemic. published online ahead of print, 2020 May 3 J Pediatr. 2020. https://doi.org/10.1016/j.jpeds.2020.04.052 50022-3476(20)30556-4.
[10] Coronavirus disease 2019 in children – United States, February 12–April 2, 2020. MMWR Morb Mortal Wkly Rep. 2020;69:422–6. https://doi.org/10.15585/mmwr.mm6914e4.